New transplant strategy aims to tame deadly bone marrow cancer
NCT ID NCT06345495
Summary
This study is testing whether giving a high dose of the drug ruxolitinib, along with busulfan chemotherapy, before a stem cell transplant can help shrink an enlarged spleen and make the transplant more successful for people with myelofibrosis. Researchers will enroll about 30 patients to see if this approach improves survival and reduces complications compared to historical rates. The goal is to better control this serious bone marrow disease through a combined treatment strategy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.